Sphere Fluidics Updates Brand Identity to Align With Ambitious, Global Commercial Growth Strategy

2023-05-23

高管变更细胞疗法

New branding reflects customer-centric approach and showcases pioneering, single cell analysis technology Rebrand follows a period of significant growth for the Company, including key leadership team appointments, state-of-the-art facility expansion, and new scientific partnerships CAMBRIDGE, England--(BUSINESS WIRE)-- Sphere Fluidics, a company developing single cell analysis systems underpinned by its patented picodroplet technology, today announced the introduction of new branding to align with its ambitious global commercial growth strategy. The update has been introduced to better reflect the Company’s customer-centric approach and showcase its pioneering single cell discovery and analysis technology, following a period of significant growth and program success. Sphere Fluidics’ range of novel cell encapsulation products for single cell analysis and isolation are aimed at easing customer workflows to accelerate scientific discovery. The Company’s proprietary platform, Cyto-Mine®, uses its picodroplet microfluidic technology and is capable of screening up to 40 million cells in several hours, while maintaining viability, to greatly increase throughput and support acceleration of biopharmaceutical discovery and development, cell therapy, and synthetic biology workflows. Sphere Fluidics’ core focus is on working with scientists to solve throughput challenges. The Company has seen a period of significant expansion over the last twelve months, including a series of new appointments within the senior leadership team, appointment of a new Chairman to the Board of Directors, expansion to its new facilities at Granta Park, Cambridge, UK, and the recent announcement of its involvement in the EU-funded research program, 3DSecret. 3DSecret is bringing together multidisciplinary experts to develop cutting-edge technologies to investigate the stochastic patterns behind metastasis at the single-cell level, to predict cancer evolution.1 Dr. Frank F Craig, CEO, Sphere Fluidics, commented: “We’re focused on transforming single cell screening and isolation, working alongside customers to streamline their workflows. The rebrand signifies our ongoing commitment to growth, the strength of our position in the market as specialists in single cell analysis, and as providers of future-proof technology in this field.” Dr. Claire Cox, Director of Global Marketing, Sphere Fluidics, added: “Our new identity is a natural progression, as we strive to ensure our brand reflects our customer-centric, forward-thinking, innovative ethos. The change in look and tone is part of this evolution, reflecting the enormous growth and positive change Sphere Fluidics has undergone in the last year, in terms of recruitment in exceptional talent and senior leadership.” Press release (24th April, 2023) Sphere Fluidics begins work with partners on 3DSecret program to investigate mechanisms of metastasis in cancer ENDS View source version on businesswire.com: Contacts Zyme Communications Lily Jeffery Tel: +44 (0)7891 477 378 Email: lily.jeffery@zymecommunications.com Source: Sphere Fluidics View this news release online at:

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构